Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Endo International

Opioid maker Endo to be monitored by Obama's former drug czar for $25K a month

Under pressure from people impacted by the nation's ongoing opioid crisis, a New York judge has confirmed Gil Kerlikowske, a former national drug czar in the Obama administration, as an outside monitor over Endo International's opioid business. The Chester County drug firm is reorganizing in bankruptcy court.

The Philadelphia Inquirer

Opioid-maker Endo $98 million bonuses are delayed in bankruptcy court

A bankruptcy judge on Thursday approved paying $93,000 in short-term incentives to employees and sales reps at Endo International but delayed a broader decision on big bonuses to corporate insiders and others.

The Philadelphia Inquirer

Opioid maker Endo paid top executives $55.5 million in bonuses before bankruptcy

Days before the money-losing opioid drug firm Endo International filed for bankruptcy last week, the company paid chief executive Blaise Coleman an $11.85 million bonus.

The Philadelphia Inquirer

From analysis to the latest developments in health,
read the most diverse news in one place.

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga

Endo, a PA opioid maker, files for bankruptcy with billions in debt

Endo International, one of the nation's larger opioid makers and with U.S. headquarters in Malvern, filed for bankruptcy protection in Manhattan on Tuesday, beset by $9.5 billion in total debt and threatened by thousands of opioid lawsuits.

The Philadelphia Inquirer

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Benzinga

Why Endo International Shares Are Getting Hammered Today

Endo International PLC (NASDAQ: ENDP) shares are trading lower by 16.86% to $0.39 after the company provided top-line results from its Phase 2 study of CCH in patients with adhesive capsulitis of the shoulder, saying "the difference compared to those study participants receiving placebo was not st

Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Benzinga

BMO Capital Maintains Market Perform Rating for Endo International: Here's What You Need To Know

BMO Capital has decided to maintain its Market Perform rating of Endo International (NASDAQ:ENDP) and lower its price target from $4.00 to $2.00. Shares of Endo International are trading down 14.79% over the last 24 hours, at $1.21 per share.

Benzinga

Expert Ratings for Endo International

Endo International (NASDAQ:ENDP) has observed the following analyst ratings within the last quarter:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Endo International Shares Are Getting Hammered Today

Endo International PLC (NASDAQ: ENDP) shares are trading lower by 34.65% at $1.32 after the company reported first-quarter earnings results and issued second-quarter guidance.

Benzinga

Endo International: Q1 Earnings Insights

Endo International (NASDAQ:ENDP) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:30 PM. Here's what investors need to know about the announcement.

StockNews.com

Should You Scoop Up Shares of Endo International on the Dip?

The shares of pharmaceutical company Endo International (ENDP) have plunged more than 50% in price over the past three months despite the company reporting mixed financial numbers in its last quarterly earnings release. In addition, considering that several analysts have lowered their price targets for the stock, is it worth…

Benzinga

Why Endo International Shares Are Falling

Endo International PLC (NASDAQ: ENDP) shares are trading lower after the company issued first-quarter EPS and sales guidance below analyst estimates.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Endo International: Q4 Earnings Insights

Endo International (NASDAQ:ENDP) reported its Q4 earnings results on Monday, February 28, 2022 at 04:30 PM. Here's what investors need to know about the announcement.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Endo International PLC

11 stories

Hutchmed

11 stories

Minerva Neurosciences

10 stories

Revelation Biosciences

10 stories

Teva Pharmaceutical Indus

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.